Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 18/20 | 0.66 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.55 |
| ▸ | GABRP | O00591 | 1/20 | 0.52 |
| ▸ | GABRD | O14764 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.52 |
| ▸ | GABRE | P78334 | 1/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.52 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158601 | 0.94 | HCAR3 (0.67) | HCAR3HCAR2GABRPGABRDGABRA1 | |
| SCHEMBL29505896 | 0.94 | HCAR3 (0.67) | HCAR3HCAR2GABRPGABRDGABRA1 | |
| Ammonia Solution, Strong SCHEMBL28249483 | 0.93 | HCAR3 (0.65) | HCAR3HCAR2GABRPGABRDGABRA1 | |
| Hydrochloric Acid SCHEMBL5789616 | 0.93 | HCAR3 (0.65) | HCAR3HCAR2GABRPGABRDGABRA1 | |
| Succinimide SCHEMBL27988812 | 0.88 | HCAR3 (0.53) | HCAR3HCAR2GABRPGABRDGABRA1 | |
| Succinic Acid SCHEMBL23070477 | 0.86 | HCAR3 (0.57) | HCAR3HCAR2GABRPGABRDGABRA1 | |
| Acetone SCHEMBL17558521 | 0.86 | NNMT (0.69) | HCAR3 | |
| SCHEMBL11005841 | 0.85 | NNMT (0.53) | HCAR3HCAR2 | |
| Acetone SCHEMBL28225377 | 0.83 | HCAR3 (0.47) | HCAR3HCAR2 | |
| Succinimide SCHEMBL28163974 | 0.82 | HCAR3 (0.53) | HCAR3HCAR2GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760772-B2 | Functionalization and purification of molecules by reversible group exchange | ILLUMINA, INC. (US) | 2023-09-19 | — | — | US | claimed |
| US-20210277043-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA, INC. (US) | 2021-09-09 | — | — | US | claimed |
| EP-2739732-B1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA INC (US) | 2020-04-22 | — | — | EP | claimed |
| US-9598453-B2 | Functionalization and purification of molecules by reversible group exchange | ILLUMINA, INC. (US) | 2017-03-21 | — | — | US | claimed |
| US-20150353592-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA, INC. (US) | 2015-12-10 | — | — | US | claimed |
| US-9040678-B2 | Functionalization and purification of molecules by reversible group exchange | ILLUMINA, INC. (US) | 2015-05-26 | — | — | US | claimed |
| CN-104160033-A | Method of coupling targeting peptides to recombinant lysosomal enzymes | AMICUS THERAPEUTICS INC | 2014-11-19 | — | — | CN | claimed |
| EP-2739732-A2 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | Illumina, Inc. (US) | 2014-06-11 | — | — | EP | claimed |
| WO-2013137922-A2 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA, INC. (US) | 2013-09-19 | — | — | WO | claimed |
| US-20130035480-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA, INC. (US) | 2013-02-07 | — | — | US | claimed |
| US-20230406874-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11760772-B2 | Functionalization and purification of molecules by reversible group exchange | ILLUMINA, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210277043-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-11021504-B2 | Functionalization and purification of molecules by reversible group exchange | ILLUMINA, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3722423-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | Illumina, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| WO-2013137922-A2 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| CN-103159854-A | Connection method of antibody and microsphere | UNIV ZHEJIANG | 2013-06-19 | — | — | CN | disclosed |
| US-20130035480-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | ILLUMINA, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| EP-1315699-A2 | HYDRAZINE-BASED AND CARBONYL-BASED BIFUNCTIONAL CROSSLINKING REAGENTS | Solulink, Incorporated (US) | 2003-06-04 | — | — | EP | disclosed |
| WO-2001070685-A2 | HYDRAZINE-BASED AND CARBONYL-BASED BIFUNCTIONAL CROSSLINKING REAGENTS | SOLULINK, INCORPORATED (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406874-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | PHAX, ALKBH1, JMJD6 | HCAR3 3713/4885HCAR2 3968/4885GABRP 1918/4885 |
| US-11021504-B2 | Functionalization and purification of molecules by reversible group exchange | PHAX, ALKBH1, JMJD6 | HCAR3 3713/4885HCAR2 3968/4885GABRP 1918/4885 |
| US-20130035480-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | PHAX, ALKBH1, JMJD6 | HCAR3 3713/4885HCAR2 3968/4885GABRP 1918/4885 |
| US-20210277043-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | PHAX, ALKBH1, JMJD6 | HCAR3 3713/4885HCAR2 3968/4885GABRP 1918/4885 |
| US-11760772-B2 | Functionalization and purification of molecules by reversible group exchange | PHAX, ALKBH1, JMJD6 | HCAR3 3713/4885HCAR2 3968/4885GABRP 1918/4885 |
| US-20150353592-A1 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE | PHAX, ALKBH1, JMJD6 | HCAR3 3713/4885HCAR2 3968/4885GABRP 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.